Aurobindo Pharma
Pharma shares regaining momentum, resuming up-trend; here’s how to shape your stock portfolio
Based on technical analysis, ICICI Direct has carved out a list of stocks that makes a multi-cap pharma stock portfolio.
3 pharma stocks set to gain 25% as cardiac remains dominant therapy in Indian pharma market
According to the brokerage firm, Lupin, Glenmark, JB Chemicals, and Cipla are likely to gain market share among listed players.
Stocks in focus: Aurobindo Pharma, Lakshmi Vilas Bank, Spicejet, Hexaware, Future Enterprises, BSE
Developments around COVID-19 vaccine, trends in coronavirus cases, oil prices and other global cues will continue to sway market sentiment
Stocks in focus: IRCTC, HDFC, Wipro, Ashoka Buildcon, IndusInd Bank, defence, aerospace stocks
Ashok Leyland, Tata Power, Aurobindo Pharma, Bharat Forge, Century Plyboards, Cummins India, Graphite India, GSFC, Gulf Oil Lubricants, Natco Pharma, NCC, Sundram Fasteners, Transport Corporation of India, are among 137 compa
Pharma earnings to reflect full COVID-19 impact in Apr-Jun quarter; 4 pharma stocks to gain up to 16%
Pharmaceutical sector will reflect the full impact of COVID-19 restrictions on the back of pre-buying in chronic therapies in March quarter, underperformance in the acute segment due to delays in elective surgeries and shut-d
Sun Pharma, Aurobindo Pharma among top stock picks from Pharma sector; CLSA sees gain up to 30%
Among pharma stocks, the top stock picks of CLSA are Sun Pharma, Cipla, Aurobindo Pharma and Cadila Healthcare, recommending a 'buy' rating on them
Aurobindo Pharma shares drop 18% as USFDA revokes VAI status for Unit IV; brokerages revise target price
Aurobindo Pharma in a BSE filing said it has received a communication that US FDA inspection at Unit IV is still open and under review.
Aurobindo Pharma shares gain over 4% as Q4 net profit climbs 39%
Aurobindo Pharma shares advanced as much as 4.32 per cent on Tuesday after the company posted a jump of 39.39 per cent in its consolidated net profit figures at Rs 562.85 crore for the quarter ended March 31, 2016
Aurobindo Pharma Q4 net profit at Rs 563 crore
Drug maker Aurobindo Pharma today posted a consolidated net profit at Rs 562.85 crore for the fourth quarter ended March 31.
Aurobindo Pharma gets US FDA nod for anaesthetic injection
The product is expected to be launched in the second quarter of 2016-17 fiscal, it added
Aurobindo Pharma gets USFDA nod for anaesthetic injection
Aurobindo Pharma has received final nod from the US health regulator to manufacture and market its anaesthetic Bupivacaine Hydrochloride injection in the American market.
Aurobindo Pharma gets USFDA nod for generic migraine drug
Aurobindo Pharma has received approval from the US health regulator to sell generic Zolmitriptan tablets, a drug used to treat migraine, in the American market.
Aurobindo Pharma gets final USFDA nod for cholesterol drug
Aurobindo Pharma has received final approval from the USFDA to manufacture and market Fenofibrate tablets, used for the treatment of high level of cholesterol, in the American market.
Aurobindo Pharma shares surge on USFDA approval for epilepsy drug
Aurobindo Pharma shares advanced over 4 per cent on Tuesday after the pharma company announced that it has received USFDA approval for its epilepsy prevention drug Lacosamide
Maruti Suzuki, HCL Tech, Yes Bank among 8 stocks that trended in Thursday’s trade
Maruti Suzuki shares closed 2.94 per cent down at Rs 3748.45 after Japense yen soared almost 3 per cent against the dollar and euro as the Bank of Japan opted out of any further moves to ease policy.
Aurobindo Pharma gets USFDA nod for blood pressure drug
Aurobindo Pharma today said it has received final approval from the US health regulator to manufacture and market generic version of blood pressure treatment drugs Amlodipine and Valsartan tablets
Aurobindo Pharma gets US FDA nod for valganciclovir tabs
Valganciclovir tablets is an anti-viral used in the treatment of Cytomegalovirus (CMV) retinitis Aurobindo Pharma received final approval from the US Food & Drug Administration (US FDA) to manufacture and market valgancic
Aurobindo Pharma receives US FDA approval for rivastigmine tartrate capsules
The product is expected to be launched in Q1 FY16-17
Aurobindo Pharma shares gain on USFDA nod for osteoporosis drug
Aurobindo Pharma shares gained over 3 per cent on Monday after it announced that the company has received final approval from USFDA to manufacture and market Naproxen Sodium Tablets
15 stocks that trended in Monday’s trade: VA Tech Wabag, Persistent Systems and more
VA Tech Wabag stocks settled 4.85 per cent up at Rs 533.20 after the company informed stock exchanges that it has bagged record orders worth Rs 5,000 crore in FY 2016.
Aurobindo Pharma receives US FDA approval for Acetylcysteine injection
The product is likely to be launched in Q1 FY16-17
Aurobindo Pharma gets USFDA nod for fungal infections tablets
The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Voriconazole tablets in the strengths of 50 mg and 200 mg, Aurobindo Pharma said in a statement.
Aurobindo Pharma gets USFDA nod for generic Tranexamic acid injection
Aurobindo Pharma has received final approval from the USFDA to manufacture and market its Tranexamic acid injection, used for treating hemophilia, in the American market. The company plans to launch the product by the end of
Aurobindo Pharma gets US FDA approval for norethindrone acetate tabs
The tablets are used in the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea Aurobindo Pharma has received the final approval from the US Food & Drug Administration
Aurobindo pharma to build pharmaceutical factory in Saudi Arabia
Indian manufacturer Aurobindo has become the latest global conglomerate to launch its factory in Saudi Arabia.
